Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy
Authors:
- Federica NovelliFNFederica Novelli
- Manuela LatorreMLManuela Latorre
- Letizia VerguraLVLetizia Vergura
- Maria Filomena CaiaffaMCMaria Filomena Caiaffa
- Gianna CamiciottoliGCGianna Camiciottoli
- Gabriella GuarnieriGGGabriella Guarnieri
- Andrea MatucciAndrea Matucci
- Luigi MacchiaLMLuigi Macchia
- Andrea VianelloAVAndrea Vianello
- Alessandra VultaggioAVAlessandra Vultaggio
- Alessandro CeliACAlessandro Celi
- Mario CazzolaMCMario Cazzola
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 31, 123-129
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) studyJournal of Allergy and Clinical Immunology, 2012
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard TherapyAnnals of Internal Medicine, 2011
- “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST studyRespiratory Medicine, 2009
- Omalizumab in patients with severe persistent allergic asthma in a real-life setting in GermanyRespiratory Medicine, 2009
- Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label studyRespiratory Medicine, 2008
- An evaluation of the cost‐effectiveness of omalizumab for the treatment of severe allergic asthmaAllergy, 2008
- Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in FranceRespiratory Medicine, 2008
- Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacyClinical & Experimental Allergy, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Asthma severity and medical resource utilisationEuropean Respiratory Journal, 2004